ArticleAdvances in radiation oncology2026
Accelerated Volume-Staged Stereotactic Radiosurgery for Large Cerebral Arteriovenous Malformations: A Single Institutional Experience.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Large cerebral arteriovenous malformations (AVMs) pose significant management challenges, particularly in achieving complete nidus obliteration without increasing the risk of symptomatic necrosis. Stereotactic radiosurgery (SRS) is an established, noninvasive treatment for inoperable AVMs. However, for large AVMs, single-stage SRS is complicated by larger volumes of irradiated normal brain and increased radiation-induced toxicity. Here, we describe our institution's accelerated volume-staged SRS (AVS-SRS) strategy for large cerebral AVMs and report long-term clinical outcomes. Methods and Materials: A retrospective analysis was performed on 19 patients with cerebral AVMs (≥6 cm Results: The median patient age was 38.5 years, with a median follow-up of 44.5 months. The median treated AVM volume was 9.6 ± 8.4 cm Conclusions: AVS-SRS with a 2- to 3-week interstage interval represents a novel treatment approach for large cerebral AVMs. It demonstrated feasible obliteration outcomes with acceptable toxicity, including a low risk of symptomatic necrosis and no post-AVS-SRS hemorrhage, in this small retrospective cohort.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.